AstraZeneca has fallen behind over the last four weeks -- at least in the U.S. Early last month, the company announced that it was temporarily pausing its late-stage clinical studies evaluating COVID-19 vaccine candidate AZD1222. AstraZeneca has since resumed its trials in multiple countries; indeed, AZD1222 is already being reviewed for potential regulatory approvals in Canada and Europe.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,